The overall effects of JX-594 were greater on lung metastases than on the primary tumor burden: JX-594 monotherapy worked significantly better than PD-1 inhibitor monotherapy on lung metastases (P < 0.01), and the JX-594 and PD-1 inhibitor combination worked better than the ICI combination (P < 0.01) (Fig. 2C). This evidence concerns the gene PDCD1 and neoplasm.